| Ident. | Authors (with country if any) | Title |
|---|
| 002A19 (2013) |
A. Frazier-Mironer [France] ; A. Cantagrel [France] ; B. Combe [France] ; V. Deschamps ; M. Dougados [France] ; R.-M. Flipo ; I. Logeart ; X. Mariette ; T. Schaeverbeke ; J. Sibilia [France] ; X. Le Loët [France] | THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study |
| 002A21 (2013) |
I. Castrej N [États-Unis] ; M. Dougados [France] ; B. Combe [France] ; F. Guillemin [France] ; B. Fautrel [France] ; T. Pincus [États-Unis] | THU0165 Predictive Value of Different Remission Criteria for a Good Functional Status Outcome: Results from the Espoir Cohort |
| 002A35 (2013) |
C. Gaujoux-Viala [France] ; L. Gossec [France] ; M. Dougados [France] ; F. Guillemin [France] ; B. Fautrel [France] | THU0134 Favorable Outcome, a New Concept for the Evaluation of Health Status in Rheumatoid Arthritis (RA) not so Easy to Achieve: Results from the Espoir Cohort |
| 002A56 (2013) |
M. Dougados [France] ; K. Kissel [Suisse] ; P. G. Conaghan [Royaume-Uni] ; E. Martin-Mola [Espagne] ; G. Schett [Allemagne] ; H. Amital [Israël] ; R. M. Xavier [Brésil] ; O. Troum [États-Unis] ; C. Bernasconi [Suisse] ; T. W. J. Huizinga [Pays-Bas] | THU0093 Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab (TCZ)-based treatment strategy with and without methotrexate (MTX) in RA: The act-ray study |
| 002D15 (2013) |
J. Sieper [Allemagne] ; B. Porter-Brown [Royaume-Uni] ; L. Thompson [Royaume-Uni] ; O. Harari [Royaume-Uni] ; M. Dougados [France] | OP0166 Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): Results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial |
| 002D42 (2013) |
T. W. J. Huizinga [Pays-Bas] ; T. Donka [Suisse] ; P. G. Conaghan [Royaume-Uni] ; E. Martin-Mola [Espagne] ; G. Schett [Allemagne] ; H. Amital [Israël] ; R. M. Xavier [Brésil] ; O. Troum [États-Unis] ; C. Bernasconi [Suisse] ; M. Dougados [France] | OP0042 Clinical and Radiographic Outcomes at Two Years and the Effect of Tocilizumab (TCZ) Discontinuation Following Sustained Remission in the Second Year of the Act-Ray Study |
| 002D90 (2013) |
C. Gaujoux-Viala [France] ; L. Gossec [France] ; M. Dougados [France] ; B. Fautrel [France] | FRI0415 Being younger and living with a partner are important determinants of sustained favorable outcome in early arthritis (EA): Results from the french espoir cohort |
| 002E07 (2013) |
M. Schiff [États-Unis] ; M. Dougados [France] ; R. Fleischmann [États-Unis] ; J. Fay [États-Unis] ; M. Maldonado [États-Unis] | FRI0257 Abatacept and anti-tnf monoclonal antibodies: efficacy and safety comparisons |
| 002E16 (2013) |
J. Sellam [France] ; S. Rouanet ; H. Hendel-Chavez ; S. Marion-Thore [France] ; C. Miceli-Richard ; B. Combe [France] ; J. Sibilia [France] ; X. Le Loët ; J. Tebib ; G. Chiocchia [France] ; R. Jourdan ; M. Dougados [France] ; Y. Taoufik ; X. Mariette | FRI0247 Serum level of interleukin 33, a novel independent predictive biomarker of clinical response to rituximab in rheumatoid arthritis: results from the smart trial |
| 002E17 (2013) |
J. H. Salmon ; P. Ravaud [France] ; T. Bardin ; P. Cacoub [France] ; A. Cantagruel [France] ; B. Combe [France] ; M. Dougados [France] ; R.-M. Flipo ; B. Godeau ; L. Guillevin [France] ; X. Le Loët ; E. Hachulla ; T. Schaeverbeke ; J. Sibilia [France] ; I. Pane [France] ; G. Baron ; X. Mariette [France] ; J.-E. Gottenberg [France] | FRI0246 Serious infusion-related reactions after rituximab in patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry |
| 002E18 (2013) |
J. Morel [France] ; M. O. Duzanski [France] ; A. Cantagrel [France] ; B. Combe [France] ; M. Dougados [France] ; R. M. Flipo ; J. E. Gottenberg [France] ; X. Mariette [France] ; O. Vittecoq ; A. Saraux ; T. Schaeverbeke ; T. Bardin [France] ; M. Soubrier ; P. Ravaud [France] ; J. Siblia [France] | FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra) |
| 002E56 (2013) |
P. Emery [Royaume-Uni] ; R. Westhovens [Belgique] ; M. Dougados [France] ; R. Alten [Allemagne] ; C. Gaillez ; C. Poncet [France] ; M. Le Bars ; A. Elegbe ; H. Genant [États-Unis] | FRI0199 In patients with established RA, abatacept efficacy is independent of baseline annual radiographic progression rate |
| 002E74 (2013) |
E. Keystone [Canada] ; S. B. Cohen [États-Unis] ; P. Emery [Royaume-Uni] ; J. M. Kremer [États-Unis] ; M. Dougados [France] ; J. E. Loveless ; C. Chung [États-Unis] ; P. Wong [États-Unis] ; P. B. Lehane [Royaume-Uni] ; H. Tyrrell [Royaume-Uni] | FRI0183 Sustained inhibition of structural damage in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors prior to rituximab treatment: 5-year data from the reflex study |
| 002F24 (2013) |
I. Castrejon [États-Unis] ; T. Pincus [États-Unis] ; M. Soubrier [France] ; Y. C. Lin [États-Unis] ; M. Dougados [France] | FRI0077 Relative efficiencies of joint counts and laboratory tests are no higher than patient-reported measures to document superior results in the guepard tight-control versus espoir routine care cohorts |
| 002F82 (2013) |
P. A. Natella ; A. Hesbert ; A. Nivina ; E. Dahan ; V. Seynave ; E. Bouscarrut ; L. Gossec [France] ; C. Roux [France] ; M. Dougados [France] ; E. Flipon | AB1413 PHA-BRIC: Therapeutic information of rheumatology patients receiving biologics in cochin hospital |
| 003129 (2013) |
J. Smolen [Autriche] ; M. Dougados [France] ; C. Gaillez ; C. Poncet [France] ; M. Le Bars ; A. Elegbe ; M. Schiff [États-Unis] | AB0543 Remission using different composite disease indices in MTX-IR RA patients treated with abatacept or infliximab, +MTX |
| 003146 (2013) |
E. Keystone [Canada] ; S. B. Cohen [États-Unis] ; P. Emery [Royaume-Uni] ; J. M. Kremer [États-Unis] ; M. Dougados [France] ; J. E. Loveless ; C. Chung [États-Unis] ; P. Wong [États-Unis] ; P. B. Lehane [Royaume-Uni] ; H. Tyrrell [Royaume-Uni] | AB0526 Sustained efficacy responses and a consistent safety profile with rituximab repeat treatment over 5 years in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors in the reflex study |
| 003160 (2013) |
B. Combe [France] ; M. Dougados [France] ; I. Logeart ; C. Lukas [France] ; X. Mariette [France] ; X. Puechal ; A. Saraux ; T. Schaeverbeke [France] | AB0516 An open-label randomized controlled study to evaluate the efficacy of etanercept (ETN) versus rituximab (RTX), in patients with active rheumatoid arthritis previously treated with RTX and TNF blockers |
| 003244 (2013) |
M. Boers [Pays-Bas] ; Y. Brault [France] ; I. Logeart [France] ; M. Dougados [France] | AB0306 The influence of the definition of patient global assessment in assessment of ACR/eular remission and minimal disease activity in rheumatoid arthritis: A 3-month cohort study in patients starting etanercept |
| 003586 (2012) |
J E Gottenberg [France] ; P. Ravaud [France] ; A. Cantagrel [France] ; B. Combe [France] ; R M Flipo [France] ; T. Schaeverbeke [France] ; E. Houvenagel [France] ; P. Gaudin [France] ; D. Loeuille [France] ; S. Rist [France] ; M. Dougados [France] ; J. Sibilia [France] ; X. Le Loët [France] ; C. Marcelli [France] ; T. Bardin [France] ; I. Pane [France] ; G. Baron [France] ; X. Mariette [France] | Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry |
| 003593 (2012) |
A. Ruyssen-Witrand [France] ; S. Rouanet [France] ; B. Combe [France] ; M. Dougados [France] ; X. Le Loët [France] ; J. Sibilia [France] ; J. Tebib [France] ; X. Mariette [France] ; A. Constantin [France] | Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab |
